Heterozygosity for a G + C mutation converting the highly conserved Gln'" (CAG) to His (CAC) was identified at the last nucleotide of exon 7 of the protein C gene in two family members with deep vein thrombosis. As the nucleotide is a part of the 5 ' splice site of intron G, it was examined how the mutation affected splicingof protein C pre-mRNA. Relevant protein C cDNA fragments were amplified with polymerase chain reaction after reverse transcription of ectopic mRNA from peripheral blood lymphocytes. Southern blot analysis and nucleotide sequencing of these fragments showed a fragment (A) corresponding to correctly spliced mRNA originating from the normal allele and a frag-HE VITAMIN K-dependent plasma glycoprotein pro-T tein C is the precursor of the anticoagulant serine proteinase-activated protein C.'" It is synthesized by hepatocytes. The cDNA4 and the encoding protein C have been cloned and completely sequenced. The 1 1.2-kb-long gene is located on chromosome no. 2 and made up of 9 exons and 8 introns. Mature protein C (amino acid residues I through 419; molecular weight [M,], ~5 6 , 0 0 0 ) is organized in three structural domain^.',^ From the NH,-terminus they are the Gla-domain, the epidermal growth factor domain, and the serine proteinase domain. Thrombin complexed with the endothelial cell membrane protein, thrombomodulin, activates protein C by cleaving the Arg'69-Le~'70 peptide bond in the NH,-terminal part of the serine proteinase region.',337 Activated protein C exerts its anticoagulant function by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa in the presence of protein S.
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Protein C deficiency is an autosomally inherited disHomozygotes or compound heterozygotes for protein C deficiency that have undetectable levels of protein C activity in plasma suffer massive thrombotic complications during the neonatal period. Heterozygotes may develop venous thromboembolic disease, usually starting after the age of 15 years (prevalence about 1 in 15,000 individuals). Defects in the protein C gene result in a decreased plasma concentration of normal protein C (type 1 defect, most frequent) or in the secretion of an abnormal dysfunctional molecule (type 2 defect). A diversity of mutations responsible for hereditary protein C deficiency have been identified. Most of these are missense or nonsense mutations in the protein coding region of the protein C gene."
Precursor mRNA splicing is the process by which introns are removed and exons joined to form mature mRNA.".l2 Splicing occurs within the spliceosome, a complex assembly of small nuclear (sn)RNAs and associated proteins. Conserved sequences at the exon-intron and intron-exon junctions denoted the 5' and 3' splice site consensus sequences, respectively, are essential for efficient and accurate splicing. Quite a number of splice site mutations have been held responsible for genetic diseases.' ',I3 These lesions abolish or reduce formation of correctly spliced mRNA or lead to production of mRNA with skipped exons or other abnormal transcripts. The present work describes a missense mutation of the protein C gene associated with deep venous thrombosis (DVT). It affects the 5' splice site of intron G at position -1.
The influence of the mutation on precursor mRNA splicing was studied using polymerase chain reaction (PCR)-amplified cDNA obtained by reverse transcription of protein C mRNA isolated from peripheral lymphocytes. Lymphocytes produce trace levels of ectopic mRNA for a number of tissue-specific proteins.I4l6 These transcripts have been proven to represent a useful material in investigating the qualitative consequences of gene defect at the mRNA level. l6
MATERIALS AND METHODS
Clinical material. Subjects under study were the proband, her parents, and her only sibling, a sister. Complete anamnesis was taken by one of the investigators (B.L.). Thrombotic events were corroborated by hospital records when possible. The presence of risk factors associated with the thromboembolic events were noted. The study was in accordance with the Helsinki Declaration of 1975 as revised in 1983 and approved by the Regional Ethical Committee.
Blood samples. Blood was obtained between 8 AM and 10 AM from healthy individuals and from patients at least 3 months after they had suffered their last thrombotic attack. Blood for determination of functional plasminogen activator inhibitor-1 (PAI-1) was collected in 0. I vol platelet-stabilizing anticoagulant (0.1 1 mol/L citric acid, 15 mmol/L theophylline, 3.7 mmol/L adenosine, 0.198 mmol/L dipyridamole, pH 5.0). Blood for other hemostatic parame- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From ters was collected in 0.1 vol 105.4 mmol/L Na,-citrate. Plasma was separated within 1 hour by centrifugation at 4°C and 3,500gfor 20 minutes (PAI-1) or 10 minutes. It was stored at -80°C until analyzed. Blood for isolation of DNA and RNA was collected in tubes containing K,-EDTA at a final concentration of 3.9 mmol/L and stored at -20°C until use in the case of DNA. Blood for isolation of RNA was processed immediately. Lymphocytes were used as a source of RNA. These cells were isolated from blood using Lymphoprep (NycoMed AS, Oslo, Norway), according to the manufacturer's instructions.
This was obtained from a recipient of a liver transplant. The specimens were excised after removal of the liver and immediately put on dry ice. The macroscopic appearance of the specimens were normal. The liver transplantation was performed due to Budd-Chian syndrome associated with polycythemia vera.
Reagents for immunoassays. Buffers used were coating buffer (2.46 mmol/L NaH,P04, 7.47 mmol/L Na,HP04, 145 mmol/L NaCl, pH 7.2), wash buffer (2.46 mmol/L NaH,PO,, 7.47 mmol/L Na,HPO,, 500 mmol/L NaCl, 0.1% [vol/vol] Tween-20, pH 7.2), and assay buffer (wash buffer supplemented with 1 mmol/L Na,-EDTA and 2.5 g/L bovine albumin [Sigma, St Louis, MO; catalogue no. A 45031). Antibodies used were monoclonal mouse IgG (F47A2) and biotinylated monoclonal IgG against human protein C (F25A2) (Novo Nordisk, Bagsvaerd, Denmark). Rabbit lgs against human protein C (A 370) and human protein S (A 384), horseradish peroxidase-conjugated rabbit Igs against human protein S (P 419), and horseradish peroxidase-conjugated swine lgs against rabbit Igs (P 2 17) were from DAKO (Glostrup, Denmark).
Coating of microtiter plates for assays of protein C and protein S. Coating of wells in 96-well microtiter plates (NUNC, Roskilde, Denmark) with antibodies in coating buffer was performed as previously described17 using 100 pL of 10 mg/L monoclonal mouse IgG against human protein C or 100 pL of rabbit Ig against human protein S diluted 1:300.
Assay of protein C. The functional and antigen concentrations of protein C in plasma were analyzed by Staclot protein C and Asserachrom protein C, respectively (both Diagnostica Stago, AsnPres, France). The antigen concentration was also analyzed by an enzyme-linked immunosorbent assay (ELISA) using two different monoclonal antibodies (MoAbs). In brief, the assay was performed at room temperature as follows. Fifty microliters of plasma diluted 200-fold in assay buffer and 50 pL of 2.6 mg/L biotinylated monoclonal protein C antibody in the same buffer were added to the antibody-coated wells. After 45 minutes of incubation, the wells were washed four times in wash buffer. This was followed by the addition of 100 pL of 1 mg/L horseradish peroxidase avidin D (Vector Laboratories, Burlingame, CA) in wash buffer to each well. After 30 minutes of incubation, the wells were washed again as described above. The final steps for measuring peroxidase activity were the same as described for the assay of urokinase-type plasminogen activator-PAL 1 (u-PA-PAL 1) complex." The assay was Calibrated against protein C control plasma (Diagnostica Stago; catalogue no. 0408). The specificity and accuracy of the assay were tested in the following ways. Analysis of plasma immunodepleted of protein C (Diagnostica Stago; catalogue no. 040 1) gave rise to an absorbance value that did not differ from that of the assay buffer. The recovery (mean t SEM [range]) of purified protein C (kindly supplied by Dr Bjorn Dahlback, Malmo, Sweden) was 82% f 5% (55% to 1 12%) when added to 15 plasma samples at a concentration of 5 mg/L. Finally, analyses of 6 plasma samples serially diluted from 1 : I 0 0 to 1 : 1,600 gave concentration estimates that were independent of the degree of dilution. The intra-assay and inter-assay variations were 3.0% and lo%, respectively, when estimated at normal levels of protein C.
Liver tissue.
Assay ofprotein S. The plasma concentration of total and nonprotein-bound protein S were analyzed by ELISA at room temperature. In brief, total protein S was analyzed by the addition of 100-pL plasma samples diluted 800-fold in assay buffer (supplemented with 30 g/L polyethylene glycol [PEG]-6000) to the antibodycoated wells. After 15 minutes of incubation, the wells were washed four times in wash buffer. Then, 100 pL of peroxidase-conjugated polyclonal anti-protein S diluted 5,000-fold in assay buffer was added to each well. After 40 minutes of incubation, the wells were washed and peroxidase activity was measured as described for the assay of protein C. In the assay of nonprotein-bound protein S, the complex between protein S and C4b-binding protein was precipitated by PEG-6000, as described by Malm et a1." The supernatant was diluted 500-fold and analyzed as described for total protein S. Assays of both total and nonprotein-bound protein S were calibrated against total protein S in protein S control plasma (Diagnostics Stago; catalogue no. 0808). The specificity and accuracy were tested in the following ways. Analysis of plasma immunodepleted of protein S (Diagnostica Stago; catalogue no. 0448) gave rise to an absorbance value that did not differ from that of the assay buffer. Finally, analyses of 7 plasma samples serially diluted 1:400 to 1 :6,400 gave concentration estimates that were independent of the degree of dilution. The intra-assay and inter-assay variations were 2.7% and 3.8% for total protein Sand 2.8% and 13% for nonproteinbound protein S, respectively, when estimated at normal levels of protein S.
Other biochemical assays. The plasma concentrations of antithrombin 111 and plasminogen were analyzed by Coatest antithrombin and Coatest plasminogen (Chromogenix AB, Miilndal, Sweden), respectively, using the ACL 300 Coagulation System (Instrumentation Laboratory, Milan, Italy). PAI-1 was analyzed as previously d e~r i b e d . '~ The following clotting assays were performed by using the ACL 300 or ACL 300 Research Coagulation System. Activated partial thromboplastin time (APTT) and coagulation factors I1 + VI1 + X (functional) were analyzed by Automated APTT (Organon Teknika, Durham, NC) and PT-SSI (NycoMed AS), respectively. Fibrinogen was analyzed by IL Test PT-Fibrinogen (Instrumentation Laboratory) using citrated plasma for calibration. The concentration of fibrinogen in the calibrator was determined spectrophotometrically at 280 nm, as previously reported.'' The thrombin time was determined by using 5. Agarosegel electrophoresis and Western blotting. Electrophoresis in 1 % (wt/vol) agarose gel was performed as described by Johanssonzo using 75 mmol/L barbiturate buffer, pH 8.6, containing 1.9 mmol/L CaCl,. The application volume was 10 pL Na,-citrate stabilized plasma. Western blotting was performed at room temperature as follows. After electrophoresis, proteins in the gel were transferred to a nitrocellulose membrane (BioRad, Richmond, CA; catalogue no. 162-0 1 13) as described by Brosstad et a1.*' Remaining sites were blocked by incubation of the nitrocellulose membrane for 1 hour in a solution of nonfat dry milk powder (30 g/L) in distilled water. This was followed by washing four times, each time for 10 minutes in Tris buffer (20 mmol/L Tris, 500 mmol/L NaCI, 0.05% [vol/vol] Tween-20, adjusted with HCI to pH 7.5). The blocked and washed nitrocellulose membrane was then incubated at least 16 hours with rabbit Ig against protein C diluted 2,000-fold in Tris
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buffer. The washing procedure was repeated and the membrane was subsequently incubated for 2 hours with peroxidase-conjugated swine Igs against rabbit Igs diluted 1,000-fold in Tris buffer. After washing five times for 10 minutes with Tris buffer and an additional wash for 10 minutes with 50 mmol/L Na-acetate, 26 mmol/L acetate acid, pH 5.0, protein C was visualized by incubation of the nitrocellulose membrane for IO minutes in 250 mg/L 3,3'-diaminobenzidine-tetrahydrocloride (DAB-fizzing-tablets; Kem-En-Tec A/ S, Copenhagen, Denmark), 0.03% (vol/vol) H202 in distilled water. All incubations above were performed under continuous shaking.
Isolation of genomic DNA. Genomic DNA was isolated from peripheral blood cells as except that 1 vol of whole blood was diluted with 3.5 vol cold buffer and that the sodium dodecyl sulfate (SDS)-disrupted nuclear pellet was incubated for I6 to 18 hours at 4°C with 40 pg/mL proteinase K (Boehringer Mannheim, Mannheim, Germany). Deproteinizing, precipitation, and quality control of DNA was performed as described by Miller et al. 23 Southern blot analysis of genomic DNA. Ten micrograms of genomic DNA from the proband and the same amount from a nonrelated normal control were digested with Msp I or Taq I (both from Promega, Madison, WI) according to the manufacturer's instructions. The digests were electrophoresed as described24 using a 0.7% (wt/vol) HSB agarose gel (Litex A/S, Vallensbzk, Denmark) and an electrophoresis buffer containing 90 mmol/L Tris-borate, 2.5 mmol/L Na2-EDTA, pH 8.3. Transfer of DNA to a Hybond-N nylon membrane (Amersham International, Amersham, UK), hybridization with protein C cDNA4 labeled with [(u-~*P]~CTP (Amersham International) by nick translation, and subsequent washing were performed as described. 24 PCR ofgenomic DNA. All nine exons, splicejunctions, and the putative promotor region in the protein C gene were amplified by PCR using the DNA Thermal Cycler from Perkin-Elmer Cetus (Norwalk, CT). Primers (Table 1) were derived from the genomic sequence' and were purchased from the Technical University of Denmark (Lyngby, Denmark). PCR amplification of exons 1,2,3, 7,8, and 9 was performed in 100 pL volumes containing 10 mmol/ L Tris-HC1, pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCI,, 0.01% (wt/vol) gelatine, 0.2 mmol/L dNTP (dATP, dCTP, dGTP, dTTP Boehringer Mannheim), I pmol/L of each primer, 0.5 to 1.5 pg genomic DNA, and 2.5 U Taq DNA polymerase (Stratagene, La Jolla, CA). The samples were overlaid with 100 pL mineral oil and subjected to denaturation (94°C for 2 minutes) followed by 30 cycles of denaturation (96°C for I minute), annealing (exon 1,67"C; exons 2, 3, and 9, 65°C; exons 7 and 8, 63°C; all for I minute), extension (72°C for 1 minute) and subsequently followed by an elongation period (72°C for 5 minutes). PCR amplification of exons 4, 5, and 6 was performed in 100 pL volumes containing 67 mmol/L Tris-HC1, pH 8.8,6.7 mmol/L MgCl,, 10 mmol/L 2-mercaptoethanol, 6.7 pmol/L Na,-EDTA, 16.6 mmol/L (NH4)2S04, 0.1 vol glycerol, 0.25 mmol/L dNTP (dATP, dCTP, dGTP, and dTTP; Boehringer Mannheim), 0.6 pmol/L ofeach primer, and 0.5 to 1.5 pg genomic DNA. The samples were overlaid with 100 pL mineral oil and denatured at 94°C for 8 minutes. After the addition of 2.5 U AmpliTaq DNA polymerase (Perkin-Elmer Cetus), the samples were subjected to 30 cycles of denaturation (94°C for 1 minute), annealing (exons 4 and 5, 68°C; exon 6, 57°C; all for 1 minute), and extension (72°C for 2 minutes). Controls without input DNA were routinely included to exclude amplification of contaminating DNA. Five microliters of each of the reaction products were electrophoresed in 3% (wt/vol) NuSieve GTG agarose gels (FMC Bioproducts, Rockland, ME) using 40 mmol/L Tris-acetate, 1 mmol/L Na2-EDTA, pH 8.1, as electrophoresis buffer and marker V (Boehringer Mannheim) as size marker.24 DNA was stained by ethidium bromide as described.24 7 Oligonucleotide used as exon 9-specific probe.
Restriction enzyme site analysis of exon 7 . Five microliters of PCR-amplified exon 7 was digested with Mae I1 (Boehringer Mannheim) according to the manufacturer's instructions and analyzed by electrophoresis in a 3% (wt/vol) NuSieve GTG agarose gel as described for PCR-amplified genomic DNA.
Isolation of total RNA from lymphocytes and liver tissue. Total cellular RNA was isolated according to Chirgwin et al," with minor modifications. Briefly, the cells were homogenized in 5 mol/L guanidinium thiocyanate, and total cellular RNA was pelleted through a cushion of 5.7 mol/L CsCl by ultracentrifugation. The RNA pellet was resuspended in 20 mmol/L Tris-HC1, 1 mmol/L Na,-EDTA, 0.2% SDS containing 200 pg/mL autodigested proteinase K (Boehringer Mannheim) and incubated for I hour at 37°C. After phenol/chloroform extraction, the RNA was ethanol-precipitated and redissolved in waterF4
Reverse transcription of total RNA and PCR amplification ofprorein C cDNA segments. This was performed by using a GeneAmp RNA PCR kit (Perkin-Elmer Cetus) according to the instructions of the manufacturer. Briefly, I pg of total RNA was reverse transcribed using random hexamers as primers. Then, 50 pmol of each of the oligonucleotide primers ( Table 1) per 100 pL reaction volume was added. Subsequently, the samples were subjected to denaturation (95OC for 5 minutes) and 30 cycles of denaturation (94°C for 1 minute), annealing (57°C for 1 minute), and extension (72°C for 1 minute). This was followed by an elongation period (72°C for 7 minutes). Controls without input RNA as well as controls in which the reverse transcription step was omitted were routinely included to exclude amplification of contaminating DNA.
Southern blot analysis of PCR-ampliJied protein C cDNA segments preparedfrom RNA. Twenty microliters of PCR-amplified cDNA segments were separated in a 3% (wt/vol) NuSieve 3: 1 agarose gel (FMC BioProducts) using 40 mmol/L Tris-acetate, pH 8.1, I mmol/L Na,-EDTA as electrophoresis buffer.24 Southern blot analysis was performed as described for genomic DNA, using the (Table I) , as a probe. The probe was 5'-end-labeled using T4 polynucleotide kinase (Pharmacia LKB Biotechnology, Uppsala, Sweden) and [y-"P]ATP (Amersham International). The sizes of the cDNA fragments on the film were estimated by interpolation on a plot of the log,,, (number of basepairs) of specific markers versus their migration distance. The size marker was prepared by Nco I and Msp I restriction enzyme cleavage of PCR-amplified exon 9 from genomic DNA from a normal subject. Partial digestion with Nco I (Boehringer Mannheim) according to the instruction of the manufacturer results in an uncleaved fragment (753 bp) and two additional fragments (605 bp and 484 bp, respectively). Complete digestion with Msp I (Boehringer Mannheim) results in one fragment (231 bp).
Second-run PCR ofprotein C cDNA segments. To sequence the PCR-amplified cDNA segments derived from lymphocyte or hepatocyte RNA, 2 pL of cDNA PCR product was amplified as described for PCR-amplified genomic DNA using nested primers (Table l).
Purification and nucleotide sequencing of PCR-amplified protein C DNA segments. Amplified genomic DNA segments or amplified cDNA segments derived from lymphocyte or hepatocyte RNA were electrophoresed as described for analysis of PCR-amplified genomic DNA products and isolated from the gel using Prep-AGene DNA purification kit (BioRad). Single-stranded DNA for nucleotide sequencing was prepared by asymmetric PCR using the same reaction conditions as described for PCR of genomic DNA except that in each reaction one of the two primers was in excess (primer concentrations 0.5 pmol/L and 0.0 1 pmol/L, respectively); the template DNA used was 50 ng ofisolated double-stranded DNA and the concentration of each dNTP was decreased to 0.05 mmol/ L. To remove excess of dNTP and to concentrate the singlestranded DNA in the asymmetric PCR product it was filtered through Ultrafree MC 30.000 NMWL filter units (Millipore, Bedford, MA). Nucleotide sequencing was performed using Sequenase kit Version 2.0 (US Biochemicals, Cleveland, OH) and relevant oligonucleotides ( Table 1) .
Numbering system for amino acids and nucleotides. The amino acids and the nucleotides were numbered according to Foster et al. ' Exons and introns were assigned the numbers 1 through 9 and the letters A through H, respectively, according to Plutzky et aL6
RESULTS

Clinical and biochemical characterization. The pro-
band is a female born in 197 I . At 17 years of age she had a spontaneous attack of phlebography-verified DVT affecting the veins in the proximal half of the left thigh. The father, born in 1940, has suffered several spontaneous attacks of phlebography-verified DVT in the lower extremities and one attack of scintigraphy-verified pulmonary embolism since the age of 33. On the left side, the deep veins on crus were affected; on the right side, the deep veins on crus and thigh were affected, as well as the superficial veins on crus. Neither the proband nor the father has any concurrent disease. The mother and the sister of the proband have no history of thromboembolism or any other disease.
In agreement with the clinical data, the plasma concentration of protein C antigen was markedly reduced in both the proband and her father when protein C was analyzed by ELISA using two different MoAbs ( Table 2 ). The same result was obtained when the plasma of the father was analyzed by ELISA using polyclonal antibodies (Asserachrom) (data not shown). The functional concentration of protein C was analyzed in the father. It was reduced to the same extent as the antigen concentration ( Table 2 ), indicating that only normal protein C is synthesized and secreted, but at a reduced rate (type 1 deficiency). This is consistent with the finding that protein C in the plasma of the father migrated as a homogeneous band with the same mobility as protein C from normal subjects when analyzed by agarose gel electrophoresis followed by Western blotting (not shown). The antigen and functional concentrations of protein C were within normal range in both the mother and the sister of the proband ( Table 2) .
The plasmas of the proband and her affected father were analyzed for hemostatic parameters other than protein C that may predict an increased risk of thromboembolism. These parameters were the anticoagulant proteins antithrombin I11 and protein S (total and nonprotein-bound), fibrinogen, thrombin time, plasminogen, PAI-I, and APTT. These parameters were all within normal range.
Gene analysis. Southern blot analysis of Msp I-or Tag
I-digested genomic DNA probed with protein C cDNA gave the same results with material from the proband and normal subjects (data not shown), indicating that no gross abnormalities were present in the protein C gene of the proband. Sequence analysis of exon 7 plus the adjacent splice junctions from the protein C gene of the proband showed a G + C mutation in one of the alleles in the last nucleotide (no. 6265) of exon 7 (Fig 1) . The mutation converts the normal Gln'84codon (CAG) to His (CAC) in the NH,-terminal part of the serine proteinase region.
Exon 7 plus adjacent splice junctions (nucleotide no. 6014-6349, 336 bp) from normal subjects contain a single Mae I1 restriction site (A 4 CGT, nucleotides no. 6294-6297) in intron G, the cleavage of which gives rise to one major 281-bp fragment. The G + C mutation at position 6265 creates an additional Mae I1 restriction site (nucleotides no. 6264-6267) at the boundary between exon 7 and intron G, the cleavage of which gives rise to one major 25 1-bp fragment. Figure 2 shows that Mae I1 restriction site analysis of PCR-amplified exon 7 plus adjacent splicejunc- 
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tions yielded the 25 I-bp as well as the 28 I-bp fragment in the case of the proband and her father, whereas it yielded only the 281-bp fragment in the case of her mother and sister (n = 3 for each subject). This is consistent with the
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Mutant allele It was shown that the father is a heterozygote (C/T). whereas the proband is a homozygote (C/C) for this polymorphism. This knowledge was used below for the characterization of the ectopic protein C mRNA from lymphocytes.
Ectopic protein C mRNA transcript analysis. The localization of the mutation to position -1 in the 5' splice site consensus sequence of intron G suggested a splicing defect."." To test this possibility, cDNA was prepared by reverse transcription of total RNA from lymphocytes. This was followed by PCR amplification of protein C cDNA using exon 6-(Ps6) and exon 9-specific primers (Pa9) ( Table I and Fig 3) . Figure 4 shows the results of agarose gel electrophoresis and Southern blot analysis of the amplified cDNA material from the proband and a normal subject using the exon 9-specific oligonucleotide probe Pa9s (Table I ) for hybridization. Four fragments, denoted A, B, C, and D, with the sizes of about 820, 670, 550, and 250 bp, respectively, were identified in the amplified cDNA from the proband (n = 2) and her father (n = I). Identical fragments, except from fragment B, were found when the cDNA from 4 normal individuals was amplified using identical PCR conditions (n = 2 in two cases, n = I in two cases). The fragments A and C fit in size to a correctly spliced transcript of the nucleotide sequence 3386-3886 in exons 6 through 9 (830 bp) and to a truncated transcript lacking exons 7 and 8 (569 bp), respectively. The patient-specific fragment B fits in size to a truncated transcript in which exon 7 is skipped (687 bp). Fragment D is most likely unspecific, as judged from the size of the fragment (250 bp) in relation to the locations of the binding regions for the amplification primers and the probe.
To characterize fragments A, B, and C, they were amplified from the affected family members and from a normal subject by a second-run PCR (n 2 2) using the nested primers Ps6i and Pa9i (Table I ). This was followed by sequence analysis of the appropriately sized second-run PCRamplified fragments using Pa9s and Pa9u as primers (Table   I and Fig 3) . A sequence of 70 to 85 bp was read in each fragment. Fragment D could not be amplified by secondrun PCR, supporting the idea that the signal is unspecific. Sequence analysis of the second-run PCR-amplified fragment A (594 bp) showed in all instances a normal reading frame with exon 7 spliced precisely to exon 8 (not shown). This result indicates that only the normal allele in the affected family members is transcribed to a correctly spliced mRNA. Sequence analysis of the second-run PCR-amplified patient-specific fragment B (45 I bp) from both the proband and her affected father showed that exon 6 is precisely spliced to exon 8, resulting in a frameshift with a stop codon beginning 89 nucleotides downstream in exon 8 (Fig 5) . fragments derived from ectopic peripheral lymphocyte mRNA or tissue-specific hepatocyte mRNA. Lymphocyte mRNA was from the proband and a normal control, whereas hepatocyte mRNA was from liver tissue of a recipient of a liver transplant. Total RNA was reverse transcribed to cDNA. Subsequently, protein C cDNA was amplified by PCR using the primers Ps6 and Pa9 (Table 1 and Fig  3) . The amplified material was electrophoresed in a 3% (vol/wt) agarose gel and hybridized with an exon 9-specific probe Pa9s (Table l ) . Four fragments A, B, C, and D, with sizes of about 820,670, 550, and 250 bp, respectively, were identified in the material derived from lymphocyte protein C mRNA of the proband. The same fragments, except B, were identified in the material derived from lymphocytes of the normal control. Hepatocyte protein C mRNA gave rise to fragments A and C, only. The sizes of the segments A through D were estimated by interpolation on plots of l og,, (number of basepairs) of markers versus their migration distance. The positions and sizes of markers are indicated to the left of the gel. The markers were prepared by restriction enzyme cleavage of PCR-amplified exon 9 from genomic protein C. Fragments A, B, and C fit in sizes to a correctly spliced transcript of the nucleotide sequence 3386-3886 of exon 6 to exon 9, a truncated transcript lacking exon 7, and a truncated transcript lacking both exon 7 and 8.
-
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Sequence analysis of the second-run PCR-amplified fragment C (333 bp) from the two affected family members as well as from the normal subject showed that exon 6 is precisely spliced to exon 9 without any shift in the reading frame.
Fragment B is specific for the proband and her father, suggesting that it originates from the mutant allele. To confirm the allelic origin of fragment B (lacking exon 7), it was assumed that the father is a heterozygote (T/C), whereas the proband is a homozygote (C/C) with respect to a neutral polymorphism at position 7228 in exon 8. Assuming a linkage between the mutation in exon 7 and the neutral polymorphism in exon 8, it was deduced that position 7228 in exon 8 on the mutant allele from the father would be a C. Fragment B from the father was amplified by a second-run PCR (n = 3) using the nested primers Ps6i and Pa8 (Table I and Fig 3) . Sequence analysis of this fragment ( I58 bp) using Ps6i as a primer confirmed that position 7228 in exon 8 of the father is a C and not a T (Fig 3) . This finding indicates that the patient-specific truncated fragment B originates from the mutant allele.
Comparison oreDNA t ranscripts ofprof f i n C mRNA.fiom lj~mphocytes and liver tissue. To investigate whether the ectopic protein C mRNA from lymphocytes was representative for the tissue-specific mRNA from hepatocytes, protein C cDNA was generated from RNA isolated from liver tissue removed from a recipient of a liver transplant. The same procedure was followed as described for preparation of protein C PCR products from lymphocyte RNA. Agarose gel electrophoresis and Southern blot analysis of the amplified material showed the presence of two fragments of the same sizes (about 820 and 550, respectively) as fragments A and C derived from ectopic protein C mRNA (Fig 4) . The two fragments were amplified by second-run PCR and sequenced (n = 2). Identical results were obtained asdescribed for the ectopic transcripts, ie, the large fragment represented the correctly spliced transcript and the small fragment represented the transcript, in which exon 6 was precisely spliced to exon 9 (not shown). It should be noted that the correctly spliced transcript was dominant in the tissue-specific-derived material, whereas the transcript lacking exons 7 and 8 was dominant in the ectopic-derived material.
DISCUSSION
This study describes a missense mutation in the protein C gene associated with a type 1 protein C deficiency and DVT.
The affected family members are heterozygotes and the inheritance is compatible with an autosomal dominant trait. The mutation (G + C) is located in the last nucleotide (no. 6265) of exon 7 and results in a change of the codon for Gln'84 (CAG) to His (CAC) in the NH,-terminal part of the serine proteinase region of protein C.
The mutation is most likely the cause of the protein C deficiency associated with a thrombotic tendency. Firstly, Southern blot analysis ofgenomic DNA and sequence analysis of all exons plus adjacent splice junctions and putative promotor region of the protein C gene did not show other abnormalities in the proband or the father. Secondly, the mutation (G6265 + C) is localized to a nucleotide sequence (CCC TGG CAG6265 in human protein C) in human and animal serine proteinases that codes for the highly conserved amino acid sequence P r~'~~-T r p '~~-G l n '~~ (residues are numbered as in human protein C). These serine proteinases include, apart from human protein C,5 bovine protein C : 6 human factor Vll,27 human and bovine factor IX,28*29 human and bovine factor X.'.31 human and bovine 
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For personal use only. on October 3, 2017. by guest www.bloodjournal.org From human factor XI," human plasma prekallikrein," human tissue-type plasminogen activator,36 human pla~minogen,~' human complement component Clr," and human and canine pre~hymotrypsinogen.'~.~ Thirdly, in a recently published database of mutations in protein C deficiency, the same mutation is listed as a homozygote case with plasma protein C activity less than 1%.
Fourthly, the mutation is localized to position -1 of the 5' splice site consensus sequence of intron G.
The localization of the mutation (G + C) to position -I in the 5' splice site of the intron G suggests defective premRNA ~plicing.".'~ The frequency of occurrence of G at this position in 5' splice sites of vertebrate genes is 77%, whereas the frequency of the mutated C is 870." To delineate how the 5' splice site mutation affected gene expression, amplified segments of cDNA transcripts of ectopic protein C mRNA from lymphocytes were analyzed. The results showed that correctly spliced protein C mRNA could be demonstrated for the normal allele, but not for the mutant allele. In addition, transcript analysis showed that the mutant allele specifically gave rise to a truncated mRNA lacking exon 7 (Figs 3 and 6) . Collectively, the results of analysis ofectopic mRNA from lymphocytes indicate that the mutation abolishes or at least drastically reduces the formation of correctly spliced mRNA.
An essential reaction during splicing is the base pairing of the 5' splice site consensus sequence (5'-CAGgtaagt-3') with the complementary sequence on U I snRNA in the spliceo- The absence of correctly spliced mRNA from the mutant allele is compatible with the observations that the genetic defect reduces the antigen and functional concentrations of protein C to the same level (type 1 deficiency) and that no abnormal protein C can be demonstrated by agarose gel electrophoresis and Western blotting. Skipping of exon 7 in the patient-specific truncated mRNA results in precise splicing of exon 6 to exon 8 and in a frameshift with a stop codon (TGA) beginning 89 nucleotides downstream in exon 8. Translation of this transcript would result in a truncated protein that lacks most ofthe serine proteinase region. Skipping of exons 7 and 8 in the truncated mRNA obtained from both patients and normal subjects results in precise in-frame splicing of exon 6 to exon 9. Translation of this transcript would result in a truncated protein lacking 87 internal amino acid residues, including three cysteine residues involved in the formation of two disulfide bridges. If the above-mentioned two transcribed protein C variants are formed, they are most likely retained and proteolytically degraded in the endoplasmic reticulum, as reported for other structural abnormal protein^!^.^^ However, it can not be excluded entirely that the truncated protein C variants are secreted but have escaped immunologic detection.
Lymphocytes were used as a source of mRNA to study pre-mRNA splicing due to the lack of access to specimens of liver tissue (the site of protein C synthesis) from the affected family members. Analysis of segments of amplified cDNA transcripts of protein C mRNA from liver tissue (removed from the recipient of a liver transplant) showed the presence of the same protein C mRNA transcripts as in normal lymphocytes, namely the correctly spliced transcript and a misspliced variant lacking exons 7 and 8 (Fig 3) . The patientspecific mRNA lacking exon 7 could not be demonstrated in the liver tissue. These results are in agreement with those of Chelly et all6 indicating that ectopic protein C mRNA transcripts can be used to study the qualitative consequences of gene defects. The correctly spliced mRNA transcript was dominant compared with the variant lacking (Fig 4) . This demonstrates that it is not possible to qualitatively extrapolate the results obtained with lymphocytes to those obtained with liver tissue. We cannot determine from our results whether the relative amounts of the amplified cDNA fragments reflect the original amounts of the normal and truncated protein C mRNA transcripts in the studied tissues or they reflect different efficiency in the reverse transcription reaction and PCR amplifi~ation!~,~~ Two other G + C mutations at position -1 within a 5' splice site have been characterized. These are in the human j3-globin gene causing j3' thala~semia~~ and in the XP group A complementing gene causing group A xerodermia pigmentosum!' In vitro studies of the first mutation showed drastic inhibition of the normal splice site and activation of several cryptic splice sites. With respect to the second mutation, no normally spliced mRNA from the mutant allele was detectable, but cryptic splice sites were activated. None of the two reported G + C mutations were associated with skipping of an upstream exon, as in the case of this study. Skipping of the upstream exon has been described in G + A and G + T mutations at position -1 of the 5' splice site of ( I ) the j3-hexominidase A gene causing Tay-Sachs ( 2 ) a collagen gene causing Ehlers-Danlos syndrome type VII,49350 (3) the antithrombin I11 gene causing recurrent venous thrombosis," and (4) purine nucleoside phosphorylase defi~iency.~~ In summary, a G + C mutation at position -1 of the 5' site consensus sequence of intron G in the protein C gene is described. The results indicate that the mutation abolishes or drastically reduces correct splicing of mRNA and leads to formation of a misspliced mRNA lacking exon 7. The gene defect can explain the phenotype of the proband and her affected father, namely a reduced plasma concentration of normal protein C (type 1 defect) associated with DVT.
